Hirsutism Clinical Trial
Official title:
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
Split-face investigation of the efficacy of applying Eflornithin cream twice daily for six months after a period with six laser treatments for hair removal.
Background: Unwanted facial hair growth is a serious problem for 5-15% of all women winch
affects their quality of life. In Denmark patients are offered six laser treatments covered
by the public health insurance. There is a lack of good follow-up treatments to this regime
that can extent the efficacy of the laser treatment. Eflornithin cream is an approved
treatment for reduction of facial hair growth which has proved to give an additional
efficiency when used in combination with laser treatments.The efficacy when used after laser
hair removal is not known.
Aim: To investigate whether an extended efficacy of laser hair removal can be achieved with
application of Eflornithin cream twice daily for six months after completion of laser
treatments.
Method: in a split-face trial to apply Eflornithin cream twice daily for six months. Outcome
measures are investigator evaluation, blinded on-site evaluation, patient's assessment score
and clinical photos.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02103608 -
Clinical Evaluation of Silk'n Glide for Face
|
N/A | |
Not yet recruiting |
NCT00495443 -
Enhanced Safety Aesthetic Laser System
|
N/A | |
Not yet recruiting |
NCT06003062 -
Suppression of Upper Lip Hair Growth Using Novel Hemp Extract
|
||
Active, not recruiting |
NCT00145288 -
Prospective Study of Patients With Hirsutism
|
Phase 2/Phase 3 | |
Completed |
NCT00152048 -
Evaluation of Eflornithine on Facial and Forearm Skin
|
Phase 4 | |
Enrolling by invitation |
NCT01461694 -
Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT00441948 -
Enhanced Safety Laser Hair Removal System
|
N/A | |
Completed |
NCT03673995 -
Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS
|
N/A | |
Recruiting |
NCT04979377 -
Prevalence of Hyperandrogenism in Type 1 Diabetes
|
||
Completed |
NCT02494297 -
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
|
||
Completed |
NCT00960310 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
|
Phase 1 | |
Completed |
NCT02793557 -
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
|
Phase 1/Phase 2 | |
Completed |
NCT01555190 -
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone
|
N/A | |
Completed |
NCT00143052 -
Bone Status and Insulin Resistance in Hirsutism
|
N/A | |
Recruiting |
NCT01338519 -
Database Study on Patients With PCOS
|
N/A | |
Recruiting |
NCT04292587 -
Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
|
||
Completed |
NCT00959335 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT00371930 -
Photodynamic Therapy for Permanent Hair Removal
|
Phase 1/Phase 2 |